Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism

 
• By Ayisha Sharma

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.  

Multicolor image of tumor cells under microscope
Several Firms Have Struggled To Develop Successful Glioma Drugs • Source: Shutterstock

More from Business

More from Scrip